These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1071 related items for PubMed ID: 19352339

  • 1. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 2. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [Abstract] [Full Text] [Related]

  • 4. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
    Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF.
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 10. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.
    Gastroenterology; 2006 Feb 19; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J.
    Clin Gastroenterol Hepatol; 2014 Mar 19; 12(3):414-22.e5. PubMed ID: 23856361
    [Abstract] [Full Text] [Related]

  • 15. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R.
    Am J Gastroenterol; 2004 Oct 19; 99(10):1984-9. PubMed ID: 15447761
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 01; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.